TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30982783

Group type: EXPERIMENTAL
Intervention: Qigong practice
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cognitive training
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Qigong practice + cognitive training
Number of subjects: 93
Study: 27778171

Group type: EXPERIMENTAL
Intervention: Single-port cholecystectomy (SPC)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Multi-port cholecystectomy (MPC)
Number of subjects: 600
Study: 25944518

Group type: EXPERIMENTAL
Intervention: Continuous intra-articular catheter (IAC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 120
Study: 23599979

Group type: EXPERIMENTAL
Intervention: Target controlled infusion of remifentanil at 1 f.Lg/L (group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Target controlled infusion of remifentanil at 2 f.Lg/L (group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Target controlled infusion of remifentanil at 3 f.Lg/L (group C)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Target controlled infusion of remifentanil at 4 f.Lg/L (group D)
Number of subjects: 120
Study: 21398087

Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine infusion (0.1, 0.15, or 0.2 mg/kg/h)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Oral ketamine (300 mg/day, interquartile range 240-382.5)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine
Number of subjects: 29
Study: 18608549

Group type: EXPERIMENTAL
Intervention: 50 g/day soy protein containing 164 mg isoflavones
Number of subjects: 52
Study: 16395099

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels > or = 40 mg/dL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels > or = 120 mg/dL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chest radiograph-confirmed alveolar consolidation (CXR-AC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-LRTI with CRP levels > or = 40 mg/dL
Number of subjects: 0

Group type: COMPARATOR
Intervention: C-LRTI alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: WHO-defined severe pneumonia
Number of subjects: 0
Study: 15590251

Group type: EXPERIMENTAL
Intervention: Lidocaine (2 mg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study: 9226527

Group type: EXPERIMENTAL
Intervention: Nizatidine (10 mg/kg/day in two doses for 8 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nizatidine
Number of subjects: 26
Study: 8434246

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ) 400 mg daily
Number of subjects: 16
Study: 2885356

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg three times a day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg and 40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29605122

Group type: EXPERIMENTAL
Intervention: Personalized RSA patient protocols
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard RSA protocol
Number of subjects: 40
Study: 27424292

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT) with external cuing and emotional regulation module
Number of subjects: 70

Group type: COMPARATOR
Intervention: Brain Health Workshop (control condition)
Number of subjects: 70
Study: 24903468

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway (NPA) insertion during sedation
Number of subjects: 216

Group type: COMPARATOR
Intervention: No nasopharyngeal airway (NPA) insertion (control group)
Number of subjects: 216
Study: 22435439

Group type: EXPERIMENTAL
Intervention: Zinc sulfate 220 mg twice daily for 90 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 20694777

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 18236303

Group type: EXPERIMENTAL
Intervention: Enhanced Condition (interactive, tailored Web‐based intervention)
Number of subjects: 2523

Group type: COMPARATOR
Intervention: Basic Condition (more linear, text‐based website)
Number of subjects: 2523
Study: 16796497

Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Traditional home care services
Number of subjects: 37
Study: 12665082

Group type: EXPERIMENTAL
Intervention: Motivational subtypes
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Continuous measure of readiness for change (URICA)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Motivational subtypes and continuous readiness measure
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: URICA
Number of subjects: 252
Study: 11112236

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (unfractionated heparin or low‐molecular‐weight heparin (reviparin) and a coumarin derivative)
Number of subjects: 1021
Study: 9273568

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 42
Study: 1350237

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.3 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3676230

Group type: EXPERIMENTAL
Intervention: Diet L (50 g lactitol/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diet S (49 g saccharose/d)
Number of subjects: 8
Study: 28988345

Group type: EXPERIMENTAL
Intervention: Partial caries removal (PCR)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Stepwise excavation (SW)
Number of subjects: 299
Study: 27567550

Group type: EXPERIMENTAL
Intervention: Sucrose drink (162 kcal)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sucralose drink (low-calorie sweetener)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Water (comparison group)
Number of subjects: 117
Study: 24375720

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-OFF
Number of subjects: 0
Study: 22460854

Group type: EXPERIMENTAL
Intervention: IntelliVent‐ASV(®)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ASV
Number of subjects: 50
Study: 20415914

Group type: EXPERIMENTAL
Intervention: Gumtone gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study: 18187077

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 89
Study: 16040409

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus petrolatum once daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Calcipotriol 0.005% ointment twice daily
Number of subjects: 19
Study: 11791028

Group type: EXPERIMENTAL
Intervention: Irbesartan (AT1 antagonist)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 11
Study: 10530535

Group type: COMPARATOR
Intervention: Intravenous analgesia/sedation (IVAS)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intraarticular lidocaine injection (IAL)
Number of subjects: 49
Study: 7793542

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 42

Group type: COMPARATOR
Intervention: Room air (Control)
Number of subjects: 42
Study: 1913614

Group type: EXPERIMENTAL
Intervention: Curaderm (0.005% BEC)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 124
Study: 6763834

Group type: EXPERIMENTAL
Intervention: Relaxation technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31618120

Group type: EXPERIMENTAL
Intervention: Logarithmic rule
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Linear rule
Number of subjects: 86

Group type: COMPARATOR
Intervention: Computer simulations
Number of subjects: 86
Study: 26880694

Group type: EXPERIMENTAL
Intervention: Mobile telehealth (MTH) intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81
Study: 25671579

Group type: EXPERIMENTAL
Intervention: Training-focused MT (8-hour, 8-week Mindfulness-based Mind Fitness Training)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Didactic-focused MT
Number of subjects: 40

Group type: COMPARATOR
Intervention: No-training control (NTC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Civilian group (CIV)
Number of subjects: 40
Study: 24833736

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 21615784

Group type: EXPERIMENTAL
Intervention: Invested with type III stone in monomaxillary PVC flask
Number of subjects: 30

Group type: COMPARATOR
Intervention: Invested with type III stone in bimaxillary PVC flask
Number of subjects: 30

Group type: COMPARATOR
Intervention: Invested with laboratory silicone in bimaxillary PVC flask
Number of subjects: 30
Study: 18583187

Group type: EXPERIMENTAL
Intervention: Silencer
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Klearway
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both MAA
Number of subjects: 16
Study: 17721100

Group type: EXPERIMENTAL
Intervention: Peer education skills intervention (n = 431)
Number of subjects: 854

Group type: COMPARATOR
Intervention: Time-equivalent attention control (n = 423)
Number of subjects: 854
Study: 15155349

Group type: EXPERIMENTAL
Intervention: 40 mL chloroprocaine 1%
Number of subjects: 150

Group type: COMPARATOR
Intervention: 40 mL chloroprocaine 0.5%
Number of subjects: 150
Study: 12370214

Group type: EXPERIMENTAL
Intervention: t10c12 CLA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CLA mixture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9842676

Group type: EXPERIMENTAL
Intervention: Ankle brace
Number of subjects: 14

Group type: COMPARATOR
Intervention: No ankle brace (Control)
Number of subjects: 14
Study: 8082071

Group type: EXPERIMENTAL
Intervention: Chemoembolization (5-fluorouracil 750 mg/m2 and recombinant alpha-2a-interferon 9-MU mixed into PVA contrast suspension)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Embolization (particulate transcatheter polyvinyl alcohol (PVA) 150-250 microns mixed with iodinated radiographic contrast)
Number of subjects: 24
Study: 2919760

Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg/kg intravenously)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental (4 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alpha-hydroxymidazolam
Number of subjects: 40
Study: 1123372

Group type: EXPERIMENTAL
Intervention: Charnley total hip replacement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ring total hip prosthesis
Number of subjects: 40
Study: 31739784

Group type: EXPERIMENTAL
Intervention: Dynamic Intraligamentary Stabilization (DIS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Internal Brace Ligament Augmentation (IBLA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Reconstruction
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: DIS or IBLA
Number of subjects: 96

Group type: COMPARATOR
Intervention: IBLA or Reconstruction
Number of subjects: 96
Study: 28072690

Group type: EXPERIMENTAL
Intervention: Insulin jet injector (regular insulin and insulin aspart)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Insulin pen (regular insulin and insulin aspart)
Number of subjects: 60
Study: 25879228

Group type: EXPERIMENTAL
Intervention: Red yeast rice and olive fruit extract (10.82 mg of monacolins and 9.32 mg of hydroxytyrosol per capsule)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Red yeast rice and olive fruit extract
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23321763

Group type: EXPERIMENTAL
Intervention: Absence of residual gastric volume monitoring
Number of subjects: 449

Group type: COMPARATOR
Intervention: Routine residual gastric volume monitoring
Number of subjects: 449
Study: 20238221

Group type: EXPERIMENTAL
Intervention: Combined connective tissue massage, Kabat's technique, kinesitherapy, and home exercise program for 9 weeks (twice a week, 1 hour per session)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home exercise program only
Number of subjects: 40
Study: 19884713

Group type: EXPERIMENTAL
Intervention: In-office bleaching with 37% carbamide peroxide (CP37)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: At-home bleaching with 10% carbamide peroxide (CP10)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of in-office (CP37) and at-home (CP10) bleaching
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study: 17124431

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg daily)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no statin treatment)
Number of subjects: 150
Study: 14691036

Group type: EXPERIMENTAL
Intervention: Slow-release paclitaxel-eluting stents
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Moderate-release paclitaxel-eluting stents
Number of subjects: 536

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 536
Study: 11578682

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) 50 microg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9695725

Group type: EXPERIMENTAL
Intervention: Entacapone (50, 100, 200, or 400 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7988585

Group type: EXPERIMENTAL
Intervention: DBS at 30 mA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supramaximal DBS3.3
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supramaximal DBS3.2
Number of subjects: 30
Study: 2656778

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 8
Study: 29164445

Group type: EXPERIMENTAL
Intervention: PEERS® Social Skills Intervention
Number of subjects: 49
Study: 28155060

Group type: EXPERIMENTAL
Intervention: Antibiotic-loaded DAC® hydrogel coating
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (without coating)
Number of subjects: 256
Study: 25162362

Group type: EXPERIMENTAL
Intervention: PEG 4000 at a dose of 0.7 g/kg (high-dose group)
Number of subjects: 92

Group type: COMPARATOR
Intervention: PEG 4000 at a dose of 0.3 g/kg (low-dose group)
Number of subjects: 92
Study: 24617232

Group type: EXPERIMENTAL
Intervention: Cake-separated moxibustion combined with lifestyle intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lifestyle intervention (control group)
Number of subjects: 60
Study: 21262562

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Artificial tears (Control)
Number of subjects: 50
Study: 19105428

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diclofenac sodium (control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between Electroacupuncture and Diclofenac sodium
Number of subjects: 40
Study: 12684359

Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT) and Sibutramine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Behavior Therapy (BT) and Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Sibutramine (after initial treatment)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Placebo to Sibutramine (after switch)
Number of subjects: 82
Study: 10194542

Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT‐11) administered via 90 min i.v. infusion
Number of subjects: 24
Study: 7772472

Group type: EXPERIMENTAL
Intervention: Collagen matrices with elastin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Collagen matrices with fibronectin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Collagen matrices with hyaluronic acid
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control wounds (no collagen matrices)
Number of subjects: 7
Study: 2211198

Group type: EXPERIMENTAL
Intervention: Pelvic plus para‐aortic irradiation
Number of subjects: 330

Group type: COMPARATOR
Intervention: Pelvic irradiation only
Number of subjects: 330
Study: 376459

Group type: EXPERIMENTAL
Intervention: NAB 365 (clenbuterol) administered at 30 micrograms b.i.d. for 3 days, then reduced to 20 micrograms b.i.d. for an average of 13 days.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Salbutamol administered at 4 mg t.i.d. for an average of 13 days.
Number of subjects: 30
Study: 31849000

Group type: EXPERIMENTAL
Intervention: Radiomics signature based on MRI features
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram incorporating radiomics signature and clinical features
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Radiomics signature in multicenter validation
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Radiomics signature and radiomics nomogram
Number of subjects: 138
Study: 31129373

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Text messaging program (Text)
Number of subjects: 800

Group type: COMPARATOR
Intervention: No Brief Intervention (No BI)
Number of subjects: 800

Group type: COMPARATOR
Intervention: No Text messaging program (No Text)
Number of subjects: 800
Study: 28526625

Group type: EXPERIMENTAL
Intervention: Resistance training one time per week (M1)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Resistance training two times per week (M2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Resistance training three times per week (M3)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Non-training control group (MCon)
Number of subjects: 88
Study: 25179260

Group type: EXPERIMENTAL
Intervention: VCD treatment
Number of subjects: 642
Study: 23345050

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ, 13.5 g/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Meropenem (MEPM, 1.5 g/day)
Number of subjects: 57
Study: 21132593

Group type: EXPERIMENTAL
Intervention: Telephone motivational interviewing (TMI)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Tailored print communication (TPC)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Combined (TPC + TMI)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 469
Study: 19720383

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over the supplementary motor area (SMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 0
Study: 17932841

Group type: EXPERIMENTAL
Intervention: 1-day application of topical 0.5% levofloxacin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3-day application of topical 0.5% levofloxacin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine (after levofloxacin applications)
Number of subjects: 100
Study: 15474628

Group type: EXPERIMENTAL
Intervention: Symptom resolution by day 14
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Symptom scores at presentation
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Symptom scores comparison
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Median time to return to work
Number of subjects: 399
Study: 11175234

Group type: EXPERIMENTAL
Intervention: Nocturnal transtracheal augmented ventilation (TTAV) at 10 L/min
Number of subjects: 15
Study: 11367663

Group type: EXPERIMENTAL
Intervention: Qingyu Jiuxin Pills (QYJXP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISD)
Number of subjects: 58
Study: 8154033

Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin (500 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo (100 ml)
Number of subjects: 28
Study: 29316960

Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) 150-300 mg twice daily for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Gabapentin (GBP) 400-800 mg three times daily for 8 weeks
Number of subjects: 38
Study: 27488235

Group type: EXPERIMENTAL
Intervention: Supervised exercise 5 d/wk for 16 wk combined with modest calorie restriction (∼0.84 MJ/d)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Global analysis of gene expression
Number of subjects: 79
Study: 24615491

Group type: EXPERIMENTAL
Intervention: Interactive virtual poverty simulation in Second Life, 2.5 hours, delivered three times over 1 year
Number of subjects: 51

Group type: COMPARATOR
Intervention: Self-study module
Number of subjects: 51
Study: 22883608

Group type: EXPERIMENTAL
Intervention: Low dose 5-ALA (15 mg capsule)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: High dose 5-ALA (50 mg capsule)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control (placebo capsule)
Number of subjects: 154
Study: 19890660

Group type: EXPERIMENTAL
Intervention: Supine posture during cycling
Number of subjects: 11

Group type: COMPARATOR
Intervention: Upright posture during cycling
Number of subjects: 11
Study: 19486056

Group type: EXPERIMENTAL
Intervention: Liquid soap containing 12% ammonium lactate + 20% urea
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo liquid soap
Number of subjects: 36
Study: 16449478

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 15459595

Group type: EXPERIMENTAL
Intervention: Amiodarone (15 mg/kg IV over 24 hours followed by 200 mg orally 3 times per day for 7 days)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sotalol (80 mg orally 2 times per day for 7 days)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Amiodarone (in patients undergoing AVR or CABG with AVR)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sotalol (in patients undergoing AVR or CABG with AVR)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 160
Study: 11174041

Group type: EXPERIMENTAL
Intervention: High-dose folic acid, vitamin B6, and vitamin B12 supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower doses of folic acid, vitamin B6, and vitamin B12 supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best medical/surgical management
Number of subjects: 0
Study: 9253332

Group type: COMPARATOR
Intervention: PTHrP (parathyroid hormone-related peptide-(1-34))
Number of subjects: 8